Hjem › Burkitts lymfom › Virginia
Kliniske studier for Burkitts lymfom i Virginia
7 studier for Burkitts lymfom søker deltakere på steder i Virginia.
Byer i Virginia
Offisiell studietekst (engelsk)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Virginia Cancer Center, Charlottesville
- Inova Fairfax Hospital, Falls Church
- Children's Hospital of The King's Daughters, Norfolk
- og 2 flere
RekruttererFase 2
366 Days – 46 Years · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- VCU Massey Comprehensive Cancer Center, Richmond
RekruttererFase 3
Alder 18 til 39 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- VCU Massey Comprehensive Cancer Center, Richmond
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Virginia Cancer Center, Charlottesville
- Children's Hospital of The King's Daughters, Norfolk
- VCU Massey Comprehensive Cancer Center, Richmond
- og 1 flere
RekruttererFase 2
365 Days · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Inova Fairfax Hospital, Falls Church
- Children's Hospital of The King's Daughters, Norfolk
- VCU Massey Comprehensive Cancer Center, Richmond
RekruttererFase 2
Alder 1 til 30 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Virginia Cancer Center, Charlottesville
- Inova Fairfax Hospital, Falls Church
- Children's Hospital of The King's Daughters, Norfolk
- og 3 flere
RekruttererFase 3
365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Richmond
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT06137118Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.